Trial Profile
A Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients With Previously Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- 08 Mar 2024 Planned End Date changed from 31 Dec 2018 to 7 Mar 2025.
- 12 Dec 2023 Results (n=541) of a secondary post-hoc analysis of SWOG Studies S0777 and S1211 assessing impact of Dexamethasone dose reductions on post-induction outcomes in subset of patients who completed all eight 3-week cycles of induction presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology